Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year
Date:2/24/2011

event is to begin to register and download or install any necessary software. A replay of the webcast will be available on www.mylan.com for approximately seven days.

About MylanMylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.

Forward Looking StatementsThis press release includes statements that constitute "forward-looking statements", including with regard to the Company's future operations and its earnings expectations. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: challenges, risks and costs inherent in business integrations and in achieving anticipated synergies; the effect of any changes in customer and supplier relationships and customer purchasing patterns; the ability to attract and retain key personnel; changes in third-party relationships; the impacts of competition; changes in economic and financial conditions of the Company's business; uncertainties and matters beyond the control of management; inherent uncertain
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
2. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
3. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
4. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
5. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
6. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
7. Mylan Confirms Four First-to-File Challenges
8. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
9. Mylans Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
10. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
11. Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)...  Caris Life Sciences® today announced the presentation ... utilized Caris Molecular Intelligence®, the company,s panomic, comprehensive ... in patients with colorectal and pancreatic cancer subtypes, ... protein 1 (PD-1) and its ligand, PD-L1. The ... American Society of Clinical Oncology Annual Meeting (ASCO) ...
(Date:5/29/2015)... SILVER SPRING, Md. and RESEARCH TRIANGLE ... Therapeutics Corporation (NASDAQ: UTHR ) announced today that ... United Therapeutics, will provide an overview and update on the ... New York City . The ... on Thursday, June 4, 2015, at 11:00 AM Eastern Time, ...
(Date:5/29/2015)... Translation is frequently listed as one of the ... used in a way that is right for a company, ... product or service offering. , Here are some of ... on a company's bottom line: , 1.    Attract bigger audience. , ... can use, why not offer it globally? Nelson Mandela once ...
(Date:5/28/2015)... , May 28, 2015  Quest Diagnostics Incorporated ... diagnostic information services, announced that it is scheduled to ... New York.  Steve Rusckowski , the company,s President ... five point strategy.  The presentation is scheduled for Tuesday, ... The presentation will be webcast live during the ...
Breaking Biology Technology:Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 2Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 4Three Ways Translation Can Help Businesses Grow 2Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2
... Calif., Aug. 28 GenVault Corporation, the,leader in ... Quebec and the Centre hospitalier affilie universitaire de,Chicoutimi ... Consortium. The,partnership included last week,s Dynamic Archive sale ... archiving and retrieving samples,that are contributed to the ...
... for successful completion of ... Phase 2b clinical trial -, ROCKVILLE, ... today announced that it will receive a $40,million payment from Novartis ... 2b trial of Albuferon(R) (albinterferon,alfa-2b) in treatment-naive patients with chronic hepatitis ...
... HIFU Revenue ... FY2007 Annual Targets Under Review, BEIJING, ... (Nasdaq: CMED ), a leading China-based,medical device company ... and high intensity focused ultrasound tumor,therapy system, today announced ...
Cached Biology Technology:GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product 2GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product 3GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product 4Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development 2Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development 3Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development 4China Medical Technologies Reports First Quarter Financial Results 2China Medical Technologies Reports First Quarter Financial Results 3China Medical Technologies Reports First Quarter Financial Results 4China Medical Technologies Reports First Quarter Financial Results 5China Medical Technologies Reports First Quarter Financial Results 6China Medical Technologies Reports First Quarter Financial Results 7China Medical Technologies Reports First Quarter Financial Results 8China Medical Technologies Reports First Quarter Financial Results 9China Medical Technologies Reports First Quarter Financial Results 10China Medical Technologies Reports First Quarter Financial Results 11China Medical Technologies Reports First Quarter Financial Results 12China Medical Technologies Reports First Quarter Financial Results 13China Medical Technologies Reports First Quarter Financial Results 14
(Date:5/29/2015)... DUBLIN , May 28, 2015 ... the addition of the "Facial Recognition Market ... User - Global Forecast to 2020" report ... years, have seen facial recognition technology become more ... technology to gain traction and investment from the ...
(Date:5/28/2015)... May 28, 2015 Industry analyst firm ... new report titled "Markets for Self-Healing Materials: 2015-2022." According ... capsule and vascular systems, biomaterials, relevant shape memory ... around $2.7 billion by 2020. The ... coverage of smart materials. Other recent n-tech reports have ...
(Date:5/27/2015)...   Codonics (codonics.com), a global ... documentation solutions and Omnicell  (omnicell.com), a ... is pleased to announce their state of ... System® (SLS), an award-winning FDA class 2 ... Anesthesia Workstation, helps prevent medication errors, streamlines ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... costs associated with storing nuclear waste and the possibility ... they may no longer be obstacles on the road ... at the University of Notre Dame, led by Thomas ... and concurrent professor of chemistry and biochemistry, showcases Notre ...
... the University of Melbourne have identified a new way ... hoped the test would be more cost effective and ... allergy in the community. Currently, an ... allergy, and while an oral food challenge is definitive ...
... A personality profile marked by overly gregarious yet anxious ... buried deep in the front center of the brain, say ... different types of brain imaging to pinpoint the suspect brain ... characterized by these behaviors. Matching the scans to scores ...
Cached Biology News:New paper by Notre Dame researchers describes method for cleaning up nuclear waste 2Test to improve peanut allergy diagnosis 2Friendly to a fault, yet tense: Personality traits traced in brain 2Friendly to a fault, yet tense: Personality traits traced in brain 3
One bottle containing 30 ml of protein solution and 0.1% sodium azide....
No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Used in May-Grunwald Giemsa stain....
Sheep polyclonal to Quinolone ( Abpromise for all tested applications). Antigen: Norfloxacin(N)conjugated to BSA...
Biology Products: